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Abstract: The influence of salsolinol on basic rat metabolism
Parkinson’s disease (PD) is associated with a broad spectrum of non-motor symptoms, which are 
poorly understood and foremost, may precede motor impairment. These symptoms include weight 
changes and gastrointestinal dysregulation. In our experiment, we applied salsolinol given peripherally 
and continuously in rats to induce changes in the enteric nervous system, which might be similar 
to those observed in PD patients. Surprisingly, we noted decrease in body weight and alteration in 
body fat contents of the animals during salsolinol exposure. The blood glucose levels, lipid profile 
and hepatic enzymes levels were assessed as well.
While lipid profile, postprandial blood glucose and hepatic enzymes levels remained indifferent, 
postprandial triglyceridemia was significantly lower in all salsolinol-treated rats in comparison with 
the control, which might be related to disturbed absorption. We also suggest that diminished body 
weight gain and lower adipose tissue accumulation in salsolinol-treated animals were due to delayed 
gastric emptying together with disturbed gut function resulting in absorptive dysfunction.
Key words: salsolinol, rat, epididymal fat pad, weight loss, Parkinson’s disease, glucose, triglycerides, 
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INTRODUCTION
Although still considered as a movement disorder, Parkinson’s disease (PD) is 
associated with a broad spectrum of non-motor symptoms, which are poorly un-
derstood and foremost, may precede motor impairment. These symptoms include 
weight changes and gastrointestinal dysregulation, such as dysphagia, delayed 
gastric emptying, nausea, constipation and faecal incontinence [1]. 
Weight loss is frequent in patients with Parkinson’s disease. Dysphagia, ano-
rexia, sense of smell and appetite loss as well as gastrointestinal dysfunction 
may be possible causes of reduced energy intake; while rigidity, tremor, and 
levodopa-induced dyskinesia may increase energy expenditure. Moreover levod-
opa may enhance glucose metabolism resulting in enhanced energy expenditure. 
Depression, antiparkinsonian drugs, medical complications such as pneumonia 
and malignancies also may facilitate weight loss in PD. Weight loss is associated 
6with malnutrition and may precipitate infection, accelerate motor, behavioral and 
autonomic impairment in PD patients [2–4]. The mechanism of weight loss in 
these patients, however, remains still undefined.
The catechol isoquinoline derivatives are compounds widely present in the 
mammalian brain and the most investigated one is referred to as salsolinol (1-me-
thyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline). It was detected for the first 
time in rat and human brain tissue samples [5, 6]. It seems to exert a wide 
range of effects on the catecholaminergic transmission and dopaminergic neu-
rons. For instance, it has been proposed that salsolinol can cause the release of 
stored catecholamines, the inhibition of catecholamine reuptake, the inhibition 
of monoamine oxidase, catechol-O-methyltransferase and tyrosine hydroxylase 
[7–9]. In addition, it has been implicated in the development of alcoholism, in 
the release of the hormone prolactin [10, 11] and in the etiopathogenesis of Par-
kinson’s disease [12–15]. 
 Salsolinol can be either endogenously synthesized from dopamine and acetal-
dehyde by salsolinol synthase and alternatively, from dopamine and pyruvic acid 
[16] or delivered exogenously with food [17]. Various toxins, tetrahydroizochinoli-
nes among them, may easily cross the intestinal barrier and reach the intestinal, 
neural pathways, initiate the processes of neurodegeneration in enteric nervous 
system and subsequently, via dorsal motor nucleus of the vagus nerve (dmX), in 
the central nervous system. According to Braak’s hypothesis, the gastric mucosa 
appears to be one of the likely sites for such entries as (1) a very large segment 
of the dmX innervates that part of the gastrointestinal tract; (2) the chymus 
remains in the stomach for a long period of time; (3) the epithelial lining of the 
stomach is thin, consists of only a single cell layer, and is susceptible to lesions 
and chronic infection; and (4) large numbers of pathological inclusions such as 
Lewy Bodies have been found in the enteric nervous system of the stomach [18]. 
Uptake of exogenous substances from the extraneuronal space is known to 
occur at the axon terminal and such material is to be transferred to the cell 
soma via retrograde axonal transport. Lots of neuroactive substances are taken 
up in this way, usually through receptor-mediated endocytosis by the presynaptic 
membrane of the next nerve cell in the neuronal chain. And, such a neurotropic 
constituent might induce conformational changes in normal -synuclein molecu-
les, provoking their aggregation and formation of Lewy Bodies [18].
The vagus nerve consists of axons, which emerge from or converge onto three 
nuclei of the medulla, including the dorsal nucleus of vagus — which sends pa-
rasympathetic output to the viscera, especially the intestines. The vagus nerve 
contributes to the bidirectional communications between the gastrointestinal tract 
and central nervous system. Afferent neurons of the vagus nerve are important 
targets of gut hormones, particularly the hormones involved in controlling food 
intake. Vago-vagal reflexes are involved in feeding homeostasis, making neuro-
modulation an attractive method for managing obesity [19].
7In animal models with vagal nerve stimulation (VNS) decreased food intake 
and weight loss are considered as the result of the stimulation of brain centers, 
the peripheral action of vagal stimulation via short cholinergic reflexes, and the 
combination of central and peripheral signals [20]. It is also hypothesized that 
the VNS decreases both food intake and body weight gain by mimicking the 
“satiety” signals transmitted from the gut to the brain, leading to the activation 
of the hypothalamic neurons that initiate the state of satiety. VNS also exerts 
anorexigenic effects on food intake and body weight gain in rats with high-fat 
diet-induced obesity [21–24]. 
Body weight, food intake and body fat content are regulated by multiple factors 
[20, 25, 26]. Despite fluctuations in the amount of food consumed, body weight 
remains stable within a relatively narrow range. Food intake together with body 
mass is controlled by both short- and long-term regulatory mechanisms [27]. 
Hypoglycemia increases food intake and stimulates vagal nerve activity [28]. Food 
transported into the stomach and duodenum activates both chemo- and mecha-
noreceptors. These signals are also transmitted via the vagus nerve to the hind 
brain where they are integrated and play a major role in short-term regulation by 
limiting the size of the meal consumed [25]. The long-term control of food intake 
involves many mediators (ghrelin, leptin, nesfatin-1, orexins and neuropeptide Y) 
and structures (nucleus of the solitary tract, arcuate nucleus of vagus nerve and 
hypothalamus) [26].
In our experiment, we applied salsolinol given peripherally and continuously 
in rats to induce changes in the enteric nervous system, which might be similar 
to those observed in PD patients. Surprisingly, we noted significant decrease in 
body weight of the animals during salsolinol exposure. We can hypothesize that 
salsolinol given peripherally can diminish food consumption and body weight via 
vagus afferents since it targets vagus nerve fibers and other centers responsible 
for appetite controlling. Thus, the aim of this work was to evaluate the effects of 
salsolinol on body mass and food intake. The blood glucose levels, lipid profile 
and hepatic enzymes levels were assessed as well. 
MATERIAL AND METHODS
Thirty-two adult male Wistar rats were studied. The animals were housed in 
individual cages. All animals were housed in the same optimal conditions, and 
food and water were provided ad libitum. During experiment, rats were fed with 
either standard diet (2.86 kcal/g, Labofeed, Poland) or with obesity-inducing hi-
gh-fat diet (4.34 kcal/g, Bento Kronen Products, Belgium). The temperature was 
maintained at 23 ± 2oC, and animals were placed on a 12 :12 h dark/light cycle. 
The Jagiellonian University Bioethical Committee approved the care and use of 
the animals (ethical approval number — 67/2009). 
8Rats were either subjected to continuous dosing of salsolinol or served as 
control. Salsolinol (salsolinol hydrochloride, Sigma, USA) in the total dose of 
200 mg/kg was dissolved in 200 μL of 0.9% solution of salt and delivered by 
ALZET osmotic mini-pumps (Durtec, USA) implanted intraperitoneally. Control 
groups were implanted with ALZET osmotic mini-pumps filled with physiological 
solution of salt. 
Prior to implantation rats were randomly divided into the following eight gro-
ups (n = 4 each): (1) rats subjected to continuous dosing of salsolinol for two 
weeks (delivery rate 0.5 μL/h, S1 group) and fed with standard diet throughout 
the entire experimental period; (2) rats subjected to continuous dosing of sal-
solinol for two weeks (delivery rate 0.5 μL/h, SF1 group) and fed with high-fat 
diet throughout the entire experimental period; (3) rats subjected to continuous 
dosing of salsolinol for four weeks (delivery rate 0.25 μL/h, S2 group) and fed 
with standard diet throughout the entire experimental period; (4) rats subjected 
to continuous dosing of salsolinol for four weeks (delivery rate 0.25 μL/h, SF2 
group) and fed with high-fat diet throughout the entire experimental period; (5) 
a control group fed with standard diet for two weeks (C1 group); (6) a control 
group fed with high-fat diet for two weeks (CF1 group); (7) a control group fed 
with standard diet for four weeks (C2 group); (8) a control group fed with high 
fat-diet for four weeks (CF2 group). Rats were starved for 12 hours and operated 
under general anesthesia induced with sodium pentobarbital given intraperitone-
ally at a dose of 0.25 mg/kg (Vetbutal, Biowet, Poland).
During the study, daily food intake and body weight were measured each mor-
ning. For each rat, the amount of daily food intake was determined by weighting 
the amount of food remaining from that given 24 h before. 
One-hour stool frequency was measured twice a week after the start of sal-
solinol infusion. Assays were performed between 10:00 and 12:00 on each day. 
Each animal was removed from its home cage and placed in a clean, clear pla-
stic cage without food nor water for 1 h. Stools were collected immediately after 
expulsion and placed in sealed tubes. The total stools were weighed to provide 
a wet weight, then dried overnight at 65oC and weighed again to provide a dry 
weight. Results were normalized to body weight. Stool water content was then 
calculated to indicate colon water absorption [29].
At the end of the experiment (day 15 or 29), following a 12-hour fast, rats were 
allowed free access to food (a mixture of high fat food and charcoal, 10 : 1) for 
1 h. Half an hour later, animals were euthanized by decapitation and the stomach 
contents were weighed to assess solid gastric emptying (results not presented 
in this study). Both epididymal fat pads, located between the cauda epididymis 
and the distal extremity of the testis, were dissected from each rat and weighed. 
The epididymal fat pad/body weight ratio was calculated by dividing the fat pad 
weight by the final body weight.
9Blood samples collected at the end of the experiment were taken into tubes 
containing aprotinin (0.6 TIU per 1 ml of blood) (Sigma-Aldrich, USA) and incu-
bated for 30 minutes at 4oC for clotting formation. After centrifugation at 1500 
g for 20 min at 4oC (Megafuge 1.0R, Heraeus Instruments), serum samples were 
collected and frozen at –80oC until further analysis. Serum aliquots were pre-
pared from each sample and glucose, hepatic enzymes (aspartate and alanine 
transaminases), triglycerides, total cholesterol as well as LDL and HDL levels were 
measured with chemistry immune-analyser Olympus AU 600. All measurements 
were performed in duplicate. Additionally, salsolinol serum level was measured 
by liquid chromatography–mass spectrometry technique.
All data are expressed as the mean and standard deviation (SD). The results 
were analyzed using a one-way analysis of variance (ANOVA) followed by a post 
hoc Tukey’s test. All statistical tests were performed using STATISTICA software 
package (StatSoft, Tulsa, USA). Statistical significance was set at p < 0.05.
RESULTS
FOOD INTAKE, BODY WEIgHT AND EPIDIDYMAL FAT PAD WEIgHT
The mean food consumption was alike however the mean weight gain was si-
gnificantly diminished in the salsolinol-treated groups of rats. Epididymal fat 
pad weight, which reflects total body fat content, was significantly higher in the 
control groups compared with the salsolinol-treated groups. 
T a b l e  1
Mean food intake, body weight and epididymal fat pad weight in salsolinol-treated (S1, SF1 — rats 
subjected to continuous dosing of salsolinol for two weeks and fed with standard or high-fat diet, 
respectively) and control group of rats (C1, CF1 — control rats fed with standard or high-fat diet, 
respectively). Asterisks (*) indicate significant differences between the salsolinol-treated and control 
groups.
group
 S1 C1 SF1 CF1
Total food intake (g) 340.4 ± 15.2  360.2 ± 24.6  238.7 ± 26.6  253.5 ± 36.3
Total food intake (kcal) 973.5 ± 43.5 1030.2 ± 70.4 1035.9 ± 115.4 1100.2 ± 157.5 
Initial body weight (g) 253.7 ± 9.9  251.5 ± 9.1  243.2 ± 4.7  220.0 ± 9.4
Final body weight (g) 312.8 ± 14.1  334.0 ± 8.9  314.1 ± 19.8  318.0 ± 4.9
Body weight gain (g)  59.1 ± 5.9*   81.6 ± 2.7   70.9 ± 18.2*   98.0 ± 13.9
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group
 S1 C1 SF1 CF1
Epididymal fat pad  
weight (EFP) (g)
  3.4 ± 0.3    3.8 ± 0.4    4.1 ± 0.4*    5.1 ± 0.2
Body weight gain/initial 
weight (%)
23.3 32.4 29.1 44.5
T a b l e  2
Mean food intake, body weight and epididymal fat pad weight in salsolinol-treated (S2, SF2 — rats 
subjected to continuous dosing of salsolinol for four weeks and fed with standard or high-fat diet, 
respectively) and control group of rats (C2, CF2 — control rats fed with standard or high-fat diet, 
respectively). Asterisks (*) indicate significant differences between the salsolinol-treated and control 
groups.
group
 S2 C2 SF2 CF2
Total food intake (g)   644.3 ± 55.1   696.9 ± 39.1   429.3 ± 36.3   509.3 ± 24.1
Total food intake (kcal)  486.9 ± 157.6  993.1 ± 111.8  863.2 ± 157.5  210.4 ± 104.6
Initial body weight (g)    23.9 ± 4.9   232.5 ± 11.9   234.2 ± 8.5   225.7 ± 7.6
Final body weight (g)   351.1 ± 33.5   366.8 ± 18.4   331.8 ± 24.9   387.5 ± 17.9
Body weight gain (g)    98.3 ± 30.5*   120.4 ± 19.7    97.6 ± 28.9*   161.8 ± 13.8
Epididymal fat pad 
weight (EFP) (g)
    3.7 ± 0.5      5.1 ± 0.5     4.9 ± 1.3*     7.8 ± 1.0
Body weight gain/
initial weight (%)
42.2 51.8 41.7 71.7
T a b l e  1  c o n t.
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Fig. 1. Total food intake (kcal/g) during the experiment in salsolinol-treated (S1, SF1 — rats subjected 
to continuous dosing of salsolinol for two weeks and fed with standard or high-fat diet, respectively; 
S2, SF2 — rats subjected to continuous dosing of salsolinol for four weeks and fed with standard 
or high-fat diet, respectively) and control rats C1, CF1 — control rats fed with standard or high-fat 
diet for two weeks, respectively; C2, CF2 — control rats fed with standard or high-fat diet for four 
weeks, respectively). No statistically significant differences between the salsolinol-treated and control 
groups were observed.
Fig. 2. Epididymal fat pad/body weight ratio (mg/g) in salsolinol-treated (S1, SF1 — rats subjected 
to continuous dosing of salsolinol for two weeks and fed with standard or high-fat diet, respectively; 
S2, SF2 — rats subjected to continuous dosing of salsolinol for four weeks and fed with standard 
or high-fat diet, respectively) and control rats (C1, CF1 — control rats fed with standard or high-fat 
diet for two weeks, respectively; C2, CF2 — control rats fed with standard or high-fat diet for four 
weeks, respectively). Asterisks (*) indicate significant differences between the salsolinol-treated and 
control groups.
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gLUCOSE
There was no statistically significant difference between the salsolinol-treated and 
control groups in the level of postprandial glycemia.
Fig. 3. Blood serum levels of postprandial glucose (mmol/l) in salsolinol-treated (S1, SF1 — rats 
subjected to continuous dosing of salsolinol for two weeks and fed with standard or high-fat diet, 
respectively; S2, SF2 — rats subjected to continuous dosing of salsolinol for four weeks and fed with 
standard or high-fat diet, respectively) and control rats (C1, CF1 — control rats fed with standard or 
high-fat diet for two weeks, respectively; C2, CF2 — control rats fed with standard or high-fat diet 
for four weeks, respectively). No statistically significant differences between the salsolinol-treated and 
control groups were observed.
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Fig. 4. Blood serum levels of postprandial triglycerides (mmol/l) in salsolinol-treated (S1, SF1 — rats 
subjected to continuous dosing of salsolinol for two weeks and fed with standard or high-fat diet, 
respectively; S2, SF2 — rats subjected to continuous dosing of salsolinol for four weeks and fed with 
standard or high-fat diet, respectively) and control rats (C1, CF1 — control rats fed with standard or 
high-fat diet for two weeks, respectively; C2, CF2 — control rats fed with standard or high-fat diet 
for four weeks, respectively). Asterisks (*) indicate significant differences between the salsolinol-treated 
and control groups.
TRIgLYCERIDES
Postprandial triglyceridemia was significantly lower in all salsolinol-treated rats 
in comparison with the control.
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LIpIDS pROFILE
There was no statistically significant difference between the salsolinol-treated and 
control groups in the level of total cholesterol, high-density lipoproteins as well 
as low-density lipoproteins.
group
 S1 C1 SF1 CF1
TC 1.87 ± 0.43 1.93 ± 0.33 2.07 ± 0.18 1.80 ± 0.31
HDL 0.55 ± 0.08 0.61 ± 0.10 0.63 ± 0.08 0.59 ± 0.07
LDL 0.78 ± 0.32 0.35 ± 0.30 0.28 ± 0.24 0.16 ± 0.02
group
S2 C2 SF2 CF2
TC 1.93 ± 0.36 2.14 ± 0.31 1.96 ± 0.23 1.82 ± 0.38
HDL 0.64 ± 0.09 0.67 ± 0.07 0.61 ± 0.50 0.52 ± 0.05
LDL 0.58 ± 0.44 0.36 ± 0.35 0.48 ± 0.51 0.17 ± 0.07
T a b l e  3
Blood serum levels (mmol/l) of total cholesterol (TC), high-density lipoproteins (HDL) as well as lo-
w-density lipoproteins (LDL) in salsolinol-treated (S1, SF1 — rats subjected to continuous dosing of 
salsolinol for two weeks and fed with standard or high-fat diet, respectively; S2, SF2 — rats subjected 
to continuous dosing of salsolinol for four weeks and fed with standard or high-fat diet, respectively) 
and control rats (C1, CF1 — control rats fed with standard or high-fat diet for two weeks, respec-
tively; C2, CF2 — control rats fed with standard or high-fat diet for four weeks, respectively). No 
statistically significant differences between the salsolinol-treated and control groups were observed.
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HEPATIC ENZYMES
There was no statistically significant difference between the salsolinol-treated and 
control groups in the level of aspartate and alanine transaminases.
group
 S1 C1 SF1 CF1
AspAT 156.3 ± 41.8 125.9 ± 14.2 121.3 ± 20.4 101.5 ± 10.5
AlAT  40.1 ± 13.9 39.9 ± 6.5 27.0 ± 2.2 27.3 ± 3.6
group
 S2 C2 SF2 CF2
AspAT 134.6 ± 25.2 124.3 ± 17.5     140.3 ± 3.8* 74.5 ± 9.7
AlAT  55.6 ± 26.0  46.7 ± 14.1 31.5 ± 5.2 24.6 ± 4.6
ONE-HOUR STOOL COLLECTION
Stool water content, an indicator of colon peristalsis and absorption, was indiffe-
rent between groups during the first two weeks after the mini-pump implanta-
tion. The difference was noted from the third week of experiment in rats treated 
with salsolinol for four weeks and fed with a standard diet — S2 = 47.70% ± 
7.22, C2 = 59.95% ± 10.97 as well as with high-fat diet SF2 = 55.88% ± 0.05, 
CF2 = 63.18% ± 5.6.
SERUM LEVEL OF SALSOLINOL
The limit of detection was set at 0.86 ng/l. Salsolinol was not detected in serum 
samples, which suggests the compound did not reach the systemic blood. 
DISSCUSSION
gastrointestinal dysfunction has been recognized as one of the most frequent 
manifestations of autonomic dysfunction in PD and may consist of disordered, ex-
cessive salivation, dysphagia, gastroparesis, decreased bowel movement frequency 
T a b l e  4
Blood serum levels of aspartate (AspAT) and alanine (AlAT) transaminases in salsolinol-treated (S1, 
SF1 — rats subjected to continuous dosing of salsolinol for two weeks and fed with standard or hi-
gh-fat diet, respectively; S2, SF2 — rats subjected to continuous dosing of salsolinol for four weeks 
and fed with standard or high-fat diet, respectively) and control rats (C1, CF1 — control rats fed 
with standard or high-fat diet for two weeks, respectively; C2, CF2 — control rats fed with standard 
or high-fat diet for four weeks, respectively). Asterisks (*) indicate significant differences between the 
salsolinol-treated and control groups.
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and defecatory dysfunction characterized by excessive straining and incomplete 
evacuation. And the enteric nervous system abnormalities have to play a role in 
the pathogenesis of the disease [30].
Salsolinol due to its structural similarity to MPTP (1-methyl-4-phenyl-1,2,3, 
6-tetrahydropyridine) might be a useful substance in modeling enteric patholo-
gies similar to those in PD. It is already well known that metabolism of salsoli- 
nol occurs through two reactions, N-methylation and oxidation. N-methylation 
of (R)-salsolinol into N-methyl-(R)-salsolinol was demonstrated in the rat stria- 
tum [31]. It was shown that methylation of (R)-salsolinol is catalyzed by two N-me-
thyltransferases with different optimum pH at 7.0 and 8.4. N-methyl-(R)-salsoli-
nol is further oxidized into 1,2-dimethyl-6,7-dihydroxyisoquinolinium by means 
of an oxidase [16, 32]. A non-enzymatic process of autoxidation has also been 
demonstrated [33]. The distribution of the N-methylated and oxidized derivatives 
of salsolinol in the human nigrostriatal pathway seems to follow a specific pat-
tern [31], which suggests that these derivatives may be involved in the function 
of dopamine neurons under physiological and pathological conditions. Notably, 
neurotoxic effects have been attributed to these metabolites, highlighting their role 
in the etiology of Parkinson’s disease [34–36]. At the same time, these metabolites 
might also be neuroprotective due to their role as hydroxyl radical scavengers. 
Therefore, it has been suggested that salsolinol might represent a “double faced” 
molecule [36, 37].
However little is known about the general influence of salsolinol on short-term 
lipids’ and carbohydrates’ absorption, their utilization as well as on body weight 
and energy storing. At the end of our experiment salsolinol was not detected in 
serum samples, which suggests the compound did not reach the systemic blood 
and must have exerted its influence through local mechanisms in the gastroin-
testinal tract. 
Meal absorption is a complex phenomenon. Postprandial hyperlipidemia and 
hyperglycemia are simultaneously present in the post-absorptive phase [38]. Ma-
intenance of a normal plasma glucose concentration requires precise matching of 
glucose utilization and endogenous glucose production or dietary glucose delive-
ry. glucose is derived from three sources: the intestinal absorption that follows 
the digestion of dietary carbohydrates, glycogenolysis and gluconeogenesis. The 
profile of postprandial hyperglycemia is determined by many factors, including 
the timing, quantity and composition of the meal [39]. The amount of cholesterol 
absorbed from the diet in humans is a major contributor to levels of choleste-
rol in circulation. Early lipid digestion, from the oral cavity to the duodenum, 
produces emulsions consisting of free cholesterol, triglycerides, free fatty acids 
and phospholipids. Bile salt emulsified triglycerides and cholesteryl esters are 
hydrolyzed by pancreatic lipase and carboxyl ester lipase. Cholesterol absorption 
is achieved through passage across brush border membranes and into intestinal 
enterocytes in the jejunum. The appeal of HDL lies in the ability to undo chole-
sterol accumulation in tissues [40]. Plasma triglyceride (Tg) level is regulated by 
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both synthesis and degradation of both very low density lipoprotein (VLDL) and 
chylomicron particles. The clearance of Tg-rich lipoproteins from the circulation 
is controlled by the actions of lipoprotein lipase and hepatic lipase, and by the 
interlipoprotein exchange of Tg by cholesteryl ester transfer protein [41]. In our 
experiment, there was no statistically significant difference between the salsolinol
-treated and control groups in the level of postprandial glycemia. Moreover, since 
there was no significant difference in the levels of aspartate and alanine transa-
minases between the salsolinol-treated and control groups it seems unlikely that 
salsolinol exerts toxic effects on hepatocytes or influences glucose metabolism. 
Postprandial triglyceridemia, however, was significantly lower in all salsolinol
-treated rats in comparison with the control. In our opinion the elevated level 
of postprandial triglycerides might be due to the access to high-fat food prior to 
decapitation. Postprandial increase of Tg was markedly lower in animals exposed 
to salsolinol in comparison with the control animals which might be related to 
the delayed gastric emptying (unpublished data) or disturbed absorption. Never-
theless, this still needs to be clarified. 
Fatty acids deposited as triacylglycerols in adipose tissue represent the primary 
energy store in animals. In periods of increased energy demand, such as fasting 
and cold exposure, stored fat is mobilized by lipolytic enzymes, which hydrolyze 
adipose triacylglycerols and release non-esterified fatty acids into the circula- 
tion [42]. When an energy deficit occurs (during fasting or exercise) triglycerides 
are broken down and fatty acids and glycerol are released into circulation. This 
release helps to supply the organism’s increased energy demands. Balance usually 
exists between these two states; but dysregulation can occur, leading to either 
an excessive storage of lipid within adipose tissue or an excessive depletion in 
states of catabolism [43]. Adipose tissue is an endocrine organ, composed of se-
veral cell types, that affects multiple other systems in a body as well as an organ 
that secretes numerous paracrine factors [44]. In rodents, fat tissue is localized 
in different depots and visceral fat easily accumulates in the epididymal fat pad, 
which is well delimitated and easy to excise. Although the epididymal fat pad 
represents only a small percentage of the total body weight, previous studies 
showed that the epididymal fat pad weight calculated as a proportion of total 
body weight highly correlates with the total body fat in mice and rats [45–47]. 
Moreover, the caudal epididymal fat pad is under the strong hormonal and nervo-
us influence [48–50]. In the present study, body composition was remarkably 
altered by salsolinol. Epididymal fat pad and body weight ratio was significantly 
lower in salsolinol-treated rats compared to the control animals.
This observation correlates with the results of body weight assessment. Altho-
ugh salsolinol treated animals consumed similar amount of food there was signi-
ficant decrease in body weight gain in animals exposed to salsolinol. Therefore, 
we conclude that salsolinol may not influence the appetite regulating mechanism 
and the reduction of body weight was due to other, probably peripheral effects. 
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We further evaluated colonic transit, which was disturbed in salsolinol-treated 
rats. Stool water content, an indicator of colon motility and absorption, was lower 
in salsolinol-treated rats after two weeks prior to the mini-pump implantation. 
Slower transit and decreased stool water content might be responsible for dimi-
nished absorption.
Similar results were obtained by Zhu et al. [51] in rat model using 6-hy-
droxydopamine (6-OHDA). The fecal outputs of the 6-OHDA group of rats were 
significantly lower than the output of the control group. Stool water content of 
the 6-OHDA group of rats was also lower than that of control group, which in-
dicates that the colon motility rats was significantly disturbed by 6-OHDA. Mo-
reover, compared with control group, the percentage of residual solid food in the 
stomach of 6-OHDA group of rats was significantly higher than that of control 
group, indicating that stomach emptying of 6-OHDA group of rats is delayed.
Furthermore, greene et al. [29] described delayed gastric empting related to 
dysfunction in the intrinsic enteric nervous system in rats during rotenone treat-
ment. Despite persistent neural dysfunction in the colonic enteric nervous system, 
he reported no lasting abnormality of stool frequency detected in rotenone-treated 
rats evaluated for three weeks. The transient decrease in stool output associated 
with rotenone infusion appeared to be correlated with body weight. Weight loss 
caused by rotenone infusion has been previously described, and was related to the 
fact that animals do not eat and drink sufficiently during early time points [52]. 
green attribute the early decrease in weight and stool frequency observed in 
his study to decreased food and water intake; however, he acknowledged that it 
is possible that the order of events is reversed, and that abnormal gI motility is 
a cause, rather than a result of decreased intake and weight loss. Our results 
seem to confirm these observations since salsolinol reduced body weight gain 
while food consumption remained not diminished. 
We conclude that absorptive dysfunction, of rather peripheral than central 
origin, resulted from delayed gastric emptying together with disturbed colon func-
tion, might be responsible for diminished body weight gain and slower adipose 
tissue accumulation in salsolinol-treated animals. 
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